We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00305253
First Posted: March 21, 2006
Last Update Posted: May 14, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
MacArthur Foundation
Information provided by (Responsible Party):
University of California, San Francisco
  Purpose
This study will test the efficacy of the NASG on women suffering from obstetric hemorrhage as compared to hemorrhaging women who do not receive the NASG.

Condition Intervention Phase
Hypovolemic Shock Hemorrhage Device: Non-pneumatic Anti-shock Garment (NASG) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Extreme Adverse Outcomes (EAO) - a Combined Outcome of Maternal Mortality or Severe Morbidity (Cardiac,Respiratory, Renal or Cerebral Dysfunction) [ Time Frame: from early pregnancy to within 3 weeks postpartum ]

Secondary Outcome Measures:
  • Blood Loss Due to Obstetric Hemorrhage [ Time Frame: within 72 hours of study enrollment ]
    cumulative blood loss measured hourly upon study admission by calibrated blood collection drape

  • Emergency Hysterectomy [ Time Frame: within 72 hours of study enrollment ]
    incidence of emergency hysterectomy for cases of uterine atony


Enrollment: 990
Study Start Date: April 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Pre-Intervention
The Pre-Intervention Phase served as the Control / Baseline group.
Experimental: Post-Intervention
Intervention used in this phase and outcomes compared to the Pre-Intervention phase.
Device: Non-pneumatic Anti-shock Garment (NASG)
In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
Other Names:
  • NASG
  • Manufactured by Zoex
  • Anti-Shock Garment
  • Life Wrap

Detailed Description:

This is a comparative, pre-post study of the Non-pneumatic Anti-Shock Garment (NASG) to establish its effectiveness in reducing maternal mortality and morbidity due to obstetrical hemorrhage. The sites are two maternity teaching hospitals in Egypt: El Galaa, in Cairo and Assiut University in Assiut.

Our main aim was to test the efficacy of the NASG on women suffering from obstetric hemorrhage as compared to hemorrhaging women who do not receive the NASG. Our primary outcome was Extreme Adverse Outcomes (EAO) - a combined outcome of maternal mortality and severe morbidity. Secondary outcomes included mean measured blood loss and incidence of emergency hysterectomy.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • blood loss from obstetric hemorrhage >= 1000 mL
  • pulse > 100 beats per minute or systolic blood pressure < 100 mmHg

Exclusion Criteria:

Absolute exclusion criteria:

  • current viable third trimester intrauterine pregnancy that can be delivered in the next 20 minutes after hemorrhage begins
  • current bleeding sites above the diaphragm.

Relative exclusion criteria:

  • history or current clinical evidence of mitral stenosis or congestive heart failure (CHF)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00305253


Locations
Egypt
Assuit University Hospital
Assiut, Egypt
El-Galaa Teaching Hospital
Cairo, Egypt
Sponsors and Collaborators
University of California, San Francisco
MacArthur Foundation
Investigators
Principal Investigator: Suellen Miller, CNM, PhD, RN University of California, San Francisco
  More Information

Additional Information:
Publications:

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00305253     History of Changes
Other Study ID Numbers: 05-84956-000-GSS
First Submitted: March 17, 2006
First Posted: March 21, 2006
Results First Submitted: July 7, 2009
Results First Posted: July 15, 2011
Last Update Posted: May 14, 2013
Last Verified: May 2013

Keywords provided by University of California, San Francisco:
maternal mortality
obstetric hemorrhage

Additional relevant MeSH terms:
Hemorrhage
Shock
Hypovolemia
Pathologic Processes